New Coya Therapeutics (COYA) director Mark H. Pavao files initial Form 3
Rhea-AI Filing Summary
Coya Therapeutics, Inc. filed an initial insider ownership report for director Mark H. Pavao on Form 3. This filing establishes his status as a reporting person and provides a baseline for tracking any future changes in his ownership of Coya Therapeutics securities.
Positive
- None.
Negative
- None.
Key Terms
Form 3, reporting person, beneficial ownership
3 terms
Form 3 regulatory
"filed an initial insider ownership report for director Mark H. Pavao on Form 3"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
reporting person regulatory
"establishes his status as a reporting person and provides a baseline"
beneficial ownership financial
"initial beneficial ownership report, creating a baseline before any future transactions"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Form 3 filing for COYA director Mark H. Pavao indicate?
The Form 3 shows that Mark H. Pavao is now an insider of Coya Therapeutics as a director. It serves as his initial beneficial ownership report, creating a baseline before any future transactions in Coya securities are disclosed.
Why is a Form 3 important for Coya Therapeutics (COYA) investors?
Form 3 is important because it identifies new insiders at Coya Therapeutics who must report their holdings. Once filed, any future trades by this director must be disclosed on Forms 4 or 5, improving transparency around insider activity.
Does the COYA Form 3 disclose derivative securities or options for the director?
The Form 3 data provided does not list any derivative securities for the director. Both the transaction list and derivative summary are empty, indicating no options or similar instruments are being reported in this initial filing.
What ownership changes can future filings show for COYA’s director?
Future filings, typically Forms 4 or 5, can show the director’s purchases, sales, grants, or option exercises in Coya Therapeutics securities. This Form 3 simply establishes the starting point for tracking those potential ownership changes.